Malaysian Healthcare Professionals' Insights on Obesity Inform Policy Strategy
Study reveals Malaysian healthcare professionals' views on obesity to guide targeted public health interventions and policy development amid rising obesity rates.
CMS Plans to Reduce Costs of Wegovy and Zepbound Enhancing Weight Loss Drug Access
CMS is set to lower costs for Wegovy and Zepbound weight loss drugs, potentially improving coverage and access for Medicare, Medicaid, and commercial insurance patients amid varied state and employer restrictions.
New Obesity Definitions and Staging Systems Enhance Risk Stratification Beyond BMI
Explore how new obesity definitions and staging systems surpass BMI limitations, offering improved risk stratification and personalized management in clinical obesity care.
Medicare Expansion for GLP-1 Agonists Balances Clinical Gains and Cost Risks
New analysis projects increased Medicare spending with expanded GLP-1 receptor agonist coverage for obesity, highlighting clinical benefits and financial challenges.
Understanding Medicare Coverage for Weight Loss Services
Explore Medicare's coverage options for weight loss services, including eligibility for obesity screening and behavioral therapy. Find out what's included and what isn't.
Medicare Coverage for Wegovy: What's the Latest Update?
Learn about Medicare's coverage of Wegovy for weight loss and cardiovascular risk.